Tafasitamab-Cxix

10月29日，诺诚健华跌0.99%，成交额1.03亿元，换手率1.67%，总市值405.34亿元。异动分析创新药1、据招股说明书：公司的主要产品之一奥布替尼（宜诺凯?）已获得国家药监局附条件批准上市用于治疗复发或难治性 MCL 和复发或难治性 CLL/SLL。根据奥布替尼的《药品注册证书》，公司需要在奥布替尼上市后完成 III 期确证性临床试验。在完成上述确证性临床试验后，奥布替尼方能获得完全批准。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入-875.51万，占比0.09%，行业排名118/159，该股当前无连续增减仓现象，主力趋势不明显；所属行业主力净流入-6.59亿，连续2日被主力资金减仓。区间今日近3日近5日近10日近20日主力净流入-875.51万354.60万-8148.36万-1.74亿-1.79亿主力持仓主力轻度控盘，筹码分布较为分散，主力成交额1.11亿，占总成交额的13.49%。技术面：筹码平均交易成本为26.70元该股筹码平均交易成本为26.70元，近期筹码减仓，但减仓程度减缓；目前股价靠近压力位23.04，谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。公司简介资料显示，诺诚健华医药有限公司位于北京市昌平区中关村生命科学园生命园路8号院8号楼，成立日期2015年11月3日，上市日期2022年9月21日，公司主营业务涉及诺诚健华医药有限公司是一家主要从事生物医药的研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域，其产品管线包括ICP-022、ICP-B04、ICP-490、ICP-192、ICP-723、ICP-022等。该公司主要在中国和美国开展业务。主营业务收入构成为：药品销售87.67%，技术授权12.04%，检测服务0.15%，研发服务0.15%。诺诚健华所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗癌治癌、抗癌药物、创新药、生物医药、中盘等。截至6月30日，诺诚健华股东户数1.52万，较上期增加13.80%；人均流通股0股，较上期增加0.00%。2025年1月-6月，诺诚健华实现营业收入7.31亿元，同比增长74.26%；归母净利润-3009.14万元，同比增长88.51%。机构持仓方面，截止2025年6月30日，诺诚健华十大流通股东中，中欧医疗健康混合A（003095）位居第六大流通股东，持股1304.78万股，相比上期增加398.07万股。富国精准医疗灵活配置混合A（005176）位居第七大流通股东，持股1258.20万股，持股数量较上期不变。鹏华医药科技股票A（001230）位居第八大流通股东，持股1020.21万股，相比上期减少501.14万股。易方达医疗保健行业混合A（110023）位居第九大流通股东，持股918.57万股，为新进股东。汇添富创新医药混合A（006113）位居第十大流通股东，持股760.38万股，为新进股东。兴全合润混合A（163406）、平安医疗健康混合A（003032）退出十大流通股东之列。风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建议。

Incyte didn’t allude to any safety concerns in relation to its decision to drop its BET inhibitor, instead attributing the move to its “ongoing pipeline prioritization efforts.” \n Incyte’s decision to scrap work on its BET inhibitor program has not surprised analysts, who pointed to safety concerns overshadowing the drug class.The biopharma, which markets Novartis-partnered blockbuster myelofibrosis drug Jakafi in the U.S., revealed this morning that it has paused development of INCB57643, a BET inhibitor Incyte had been evaluating in a phase 2 myelofibrosis study in combination with Jakafi.William Blair analysts noted this morning that the BET inhibitor had been due to enter a phase 3 study for myelofibrosis this year but added that they were “not surprised by the program’s discontinuation due to safety concerns for the class.”Novartis was stung by these concerns last year when it detected an imbalance in the rate of acute myeloid leukemia in a phase 3 study of myelofibrosis drug pelabresib, which it acquired as part of its buyout of MorphoSys. It led the Swiss pharma to delay its approval plans for the BET inhibitor, resulting in an $800 million impairment in the pharma’s finances.Earlier this year, the FDA slapped a clinical hold on a phase 1b plaque psoriasis study of Vyne Therapeutics’ BET inhibitor after testicular toxicity was reported in dogs from a separate, nonclinical test.Incyte didn’t allude to any safety concerns in relation to its decision to drop INCB57643, instead attributing the move to its “ongoing pipeline prioritization efforts.” The company is also halting work on an anti-CD122 drug dubbed INCA034460, it said in its third-quarter earnings document. Incyte had been assessing the asset in a phase 1 study for vitiligo.Those same prioritization efforts mean the biopharma will also stop developing povorcitinib in chronic spontaneous urticaria (CSU), according to the release. Despite narrowing the focus for the JAK1 inhibitor, Incyte is still planning to submit the drug to European regulators for approval as a treatment for moderate to severe hidradenitis suppurativa (HS) before the end of the year, with an application to the FDA to follow in early 2026. The company arrived at the European Association of Dermatology and Venereology conference last month armed with longer-term HS data showing nearly 60% of patients who received povorcitinib achieved a 50% reduction in inflammatory lesions at Week 24.While Incyte is no longer considering povorcitinib as a CSU treatment, the company is expecting a phase 3 readout in prurigo nodularis—as well as data from a phase 2 trial in asthma—to arrive next year.Anchored by blockbuster Jakafi, Incyte’s array of approved meds include fast-growing JAK cream Opzelura, lymphoma med Monjuvi and PD-1 inhibitor Zynyz, among others.